FDA Approves Moderna's Lower-Dose COVID Vaccine With Usage Limits

The FDA has approved Moderna's new lower-dose COVID-19 vaccine, mNexspike, with specific limitations on who can receive it. The vaccine is approved for adults 65 and older and for people aged 12-64 with health conditions that increase their coronavirus risk. These restrictions mirror similar limitations placed on Novavax's COVID-19 vaccine and represent a departure from previous U.S. vaccination policies.